Alzheimer's disease infusion therapy - Kisunla (Donanemab)

Did you know that Harbour Neurology in Sydney now offers infusion therapy against Alzheimer's disease? After over a century of research, the new age of anti-amyloid therapies are here, with the aim of slowing Alzheimer's disease by up to 35%. Kisunla (Donanemab) targets the bad amyloid protein that builds up around neurons in Alzheimer's disease, causing plaques. There eventually trigger dysfunction, inflammation, and a degenerative loss of neurons leading to functional decline.

The hope is that by targeting amyloid protein using a 30-minute intravenous infusion, given monthly for up to 18 months, that the condition will be slowed down, but there are important side effects to be considered. Patients on infusion therapy are carefully monitoring for any signs of brain swelling, bleeding or inflammation called Amyloid Related Imaging Abnormalities (ARIA) using clinical assessment and repeat MRI brain imaging. Patients are observed carefully after having the medication, and at current there is a significant cost to having it, as it is not listed on the Pharmaceutical Benefits Scheme in Australia (PBS).

Donanemab is for those patients who already have early Alzheimer's disease, or, who have mild cognitive impairment with evidence of amyloid buildup. There are additional criteria needed to assess a patient's suitability for the medication.

For those wanting to understand their risk of developing dementia and prevent it where possible, there are 14 modifiable risk factors. A neurologist can assist in reducing risk and advising on lifestyle and medication approaches for an individual. Other conditions that can mimic Alzheimer's disease can also be considered and managed.

You can find out more about our Alzheimer's infusion service in the video below: